Jean-François Chatal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jean-François Chatal has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Barbet
GIP Arronax, Saint-Herblain, France
12 shared publications - Françoise Kraeber-Bodéré
Nantes Université, CHU Nantes, Nantes Cedex 1, France
8 shared publications - Caroline Bodet-Milin
Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Nantes, France
4 shared publications - David M. Goldenberg
Immunomedics, Inc., Morris Plains, New Jersey.
4 shared publications - Alain Faivre-Chauvet
Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI(2)NA, 8 quai Moncousu, 44007 Nantes Cedex, France
3 shared publications - Caroline Rousseau
ICO-Gauducheau, CRCNA, UMR 892 Inserm, 6299 CNRS, Université de Nantes
3 shared publications
Latest Publications
- 25 April 2018
- Published by Springer Nature
- p. 119-137
Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer?
- 25 April 2018
- Published by Springer Nature
- p. 119-137
Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer?
- 25 April 2018
- Published by Springer Nature
- p. 139-153
Prospects for Enhancing Efficacy of Radioimmunotherapy
- 25 April 2018
- Published by Springer Nature
- p. 139-153
Prospects for Enhancing Efficacy of Radioimmunotherapy
- Open Access
- 18 August 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (12) , 2166-2168
ImmunoPET to help stratify patients for targeted therapies and to improve drug development
- 18 August 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (12) , 2166-2168
Open AccessImmunoPET to help stratify patients for targeted therapies and to improve drug development
- 29 October 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (3) , 329-331
Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?
- 29 October 2015
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (3) , 329-331
Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?
- Open Access
- 11 September 2015
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 2, 65
Story of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging
Rubidium-82 has a long story, starting in 1954. After preclinical studies in dogs showing that myocardial uptake of this radionuclide was directly proportional to myocardial blood flow (MBF), clinical studies were performed in the 80s leading to an approval in the USA in 1989. From that time, thousands of patients have been tested and their results have been reported in three meta-analyses. Pooled patient-based sensitivity and specificity were, respectively, 0.91 and 0.90. By comparison with (99m)Tc-SPECT, (82)Rb PET had a much better diagnostic accuracy, especially in obese patients with body mass index ≥30 kg/m(2) (85 versus 67% with SPECT) and in women with large breasts. A great advantage of (82)Rb PET is its capacity to accurately quantify MBF. Quite importantly, it has been recently shown that coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity. Moreover, coronary flow reserve is a functional parameter particularly useful in the estimate of microvascular dysfunction, such as in diabetes mellitus. Due to the very short half-life of rubidium-82, the effective dose calculated for a rest/stress test is roughly equivalent to the annual natural exposure and even less when stress-only is performed with a low activity compatible with a good image quality with the last generation 3D PET scanners. There is still some debate on the relative advantages of (82)Rb PET with regard to (99m)Tc-SPECT. For the last 10 years, great technological advances substantially improved performances of SPECT with its accuracy getting closer to this of (82)Rb/PET. Currently, the main advantages of PET are its capacity to accurately quantify MBF and to deliver a low radiation exposure.
- 11 September 2015
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 2, 65
Open AccessStory of Rubidium-82 and Advantages for Myocardial Perfusion PET Imaging
Rubidium-82 has a long story, starting in 1954. After preclinical studies in dogs showing that myocardial uptake of this radionuclide was directly proportional to myocardial blood flow (MBF), clinical studies were performed in the 80s leading to an approval in the USA in 1989. From that time, thousands of patients have been tested and their results have been reported in three meta-analyses. Pooled patient-based sensitivity and specificity were, respectively, 0.91 and 0.90. By comparison with (99m)Tc-SPECT, (82)Rb PET had a much better diagnostic accuracy, especially in obese patients with body mass index ≥30 kg/m(2) (85 versus 67% with SPECT) and in women with large breasts. A great advantage of (82)Rb PET is its capacity to accurately quantify MBF. Quite importantly, it has been recently shown that coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity. Moreover, coronary flow reserve is a functional parameter particularly useful in the estimate of microvascular dysfunction, such as in diabetes mellitus. Due to the very short half-life of rubidium-82, the effective dose calculated for a rest/stress test is roughly equivalent to the annual natural exposure and even less when stress-only is performed with a low activity compatible with a good image quality with the last generation 3D PET scanners. There is still some debate on the relative advantages of (82)Rb PET with regard to (99m)Tc-SPECT. For the last 10 years, great technological advances substantially improved performances of SPECT with its accuracy getting closer to this of (82)Rb/PET. Currently, the main advantages of PET are its capacity to accurately quantify MBF and to deliver a low radiation exposure.
- Open Access
- 11 February 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (2) , 3932-3954
Tumor Immunotargeting Using Innovative Radionuclides
This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.
- 11 February 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (2) , 3932-3954
Open AccessTumor Immunotargeting Using Innovative Radionuclides
This paper reviews some aspects and recent developments in the use of antibodies to target radionuclides for tumor imaging and therapy. While radiolabeled antibodies have been considered for many years in this context, only a few have reached the level of routine clinical use. However, alternative radionuclides, with more appropriate physical properties, such as lutetium-177 or copper-67, as well as alpha-emitting radionuclides, including astatine-211, bismuth-213, actinium-225, and others are currently reviving hopes in cancer treatments, both in hematological diseases and solid tumors. At the same time, PET imaging, with short-lived radionuclides, such as gallium-68, fluorine-18 or copper-64, or long half-life ones, particularly iodine-124 and zirconium-89 now offers new perspectives in immuno-specific phenotype tumor imaging. New antibody analogues and pretargeting strategies have also considerably improved the performances of tumor immunotargeting and completely renewed the interest in these approaches for imaging and therapy by providing theranostics, companion diagnostics and news tools to make personalized medicine a reality.
- 14 November 2014
- Published by Springer Nature
- p. 441-460
New Advances in Radioimmunotherapy for the Treatment of Cancers
- 14 November 2014
- Published by Springer Nature
- p. 441-460
New Advances in Radioimmunotherapy for the Treatment of Cancers
- 13 June 2013
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 40 (9) , 1373-1376
Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?
- 13 June 2013
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 40 (9) , 1373-1376
Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 159
Improvement of Radioimmunotherapy Using Pretargeting
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabelled monoclonal antibodies and receptor binding agents. Conventional Radioimmunotherapy (RIT) is now an established and important tool in the treatment of hematologic malignancies such as Non-Hodgkin lymphoma. For solid malignancies, the efficacy of RIT has not been as successful due to lower radiosensitivity, difficult penetration of the antibody into the tumor and potential excessive radiation to normal tissues. Innovative approaches have been developed in order to enhance tumor absorbed dose while limiting toxicity to overcome the different limitations due to the tumor and host characteristics. Pretargeting techniques (pRIT) are a promising approach that consists of decoupling the delivery of a tumor monoclonal antibody (mAb) from the delivery of the radionuclide. This results in a much higher tumor-to-normal tissue ratio and is favorable for therapy as well and imaging. This includes various strategies based on avidin/streptavidin-biotin, DNA-complementary DNA and bispecific antibody-hapten bindings. PRIT continuously evolves with the investigation of new molecular constructs and the development of radiochemistry. Pharmacokinetics improve dosimetry depending on the radionuclides used (alpha, beta and Auger emitters) with prediction of tumor response and host toxicities. New constructs such as the Dock and Lock technology allow production of a variety of mABs directed against tumor-associated antigens. Survival benefit has already been shown in medullary thyroid carcinoma. Improvement in delivery of radioactivity to tumors with these pretargeting procedures associated with reduced hematologic toxicity will become the next generation of RIT. The following review addresses actual technical and clinical considerations and future development of pRIT.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 159
Open AccessImprovement of Radioimmunotherapy Using Pretargeting
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabelled monoclonal antibodies and receptor binding agents. Conventional Radioimmunotherapy (RIT) is now an established and important tool in the treatment of hematologic malignancies such as Non-Hodgkin lymphoma. For solid malignancies, the efficacy of RIT has not been as successful due to lower radiosensitivity, difficult penetration of the antibody into the tumor and potential excessive radiation to normal tissues. Innovative approaches have been developed in order to enhance tumor absorbed dose while limiting toxicity to overcome the different limitations due to the tumor and host characteristics. Pretargeting techniques (pRIT) are a promising approach that consists of decoupling the delivery of a tumor monoclonal antibody (mAb) from the delivery of the radionuclide. This results in a much higher tumor-to-normal tissue ratio and is favorable for therapy as well and imaging. This includes various strategies based on avidin/streptavidin-biotin, DNA-complementary DNA and bispecific antibody-hapten bindings. PRIT continuously evolves with the investigation of new molecular constructs and the development of radiochemistry. Pharmacokinetics improve dosimetry depending on the radionuclides used (alpha, beta and Auger emitters) with prediction of tumor response and host toxicities. New constructs such as the Dock and Lock technology allow production of a variety of mABs directed against tumor-associated antigens. Survival benefit has already been shown in medullary thyroid carcinoma. Improvement in delivery of radioactivity to tumors with these pretargeting procedures associated with reduced hematologic toxicity will become the next generation of RIT. The following review addresses actual technical and clinical considerations and future development of pRIT.
- 29 July 2012
- Published by Springer Nature
- p. 315-321
Medullary Thyroid Carcinoma